Special Issue "Research in Aggressive Brain Tumors: Biology and Precision Therapy"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (31 December 2021).

Special Issue Editor

Dr. Daniela Lötsch
E-Mail Website
Guest Editor
Department of Neurosurgery, Medical University Vienna, 1090 Vienna, Währinger Gürtel 18-20, Austria;
Comprehensive Cancer Center-Central Nervous System Tumors Unit, Medical University Vienna, 1090 Vienna, Austria
Interests: brain tumor; glioblastoma; ependymoma; targeted therapy; heterogeneity; biomarker; resistance; oncogenic driver

Special Issue Information

Dear Colleagues,

Primary brain tumors affect both children and adults and represent a substantial source of morbidity and mortality worldwide. Among the adult population, glioblastoma is the most common malignant histological type, characterized by a dismal prognosis of less than 2 years, despite multidisciplinary treatment that includes surgical resection and combined radio- chemotherapy. In children, brain tumors including medulloblastoma, gliomas, and ependymomas, rank first among all solid cancers. Survival rates strongly depend on tumor grading and therapeutic options, which are often limited in pediatric patients.

During the last decade, comprehensive genomics and epigenomics studies based on bulk or single-cell omics technologies have elucidated new aspects of molecular alterations and inter-tumor and intra-tumor heterogeneity. These findings improved diagnosis and led to the discovery of new brain tumor subtypes with distinct molecular alterations. Thus, targeted therapies, including MEK and BRAF V600E inhibitors, have been implemented in treatment regimens of pediatric and adult brain tumor patients. However their efficacy is limited due to the presence of multiple genetic abnormalities, limited transport via the blood–brain barrier, intrinsic or acquired resistance mechanisms, or unacceptable side-effects.

This Special Issue will bring the knowledge of genetic, epigenetic, developmental, and microenvironmental heterogeneity into a (pre)clinically relevant context for aggressive pediatric and adult brain tumors

Dr. Daniela Lötsch
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain tumor
  • targeted therapy
  • heterogeneity
  • resistance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives
Cancers 2022, 14(2), 443; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14020443 - 17 Jan 2022
Viewed by 357
Abstract
Glioblastoma is the most common and malignant primary brain tumor, defined by its highly aggressive nature. Despite the advances in diagnostic and surgical techniques, and the development of novel therapies in the last decade, the prognosis for glioblastoma is still extremely poor. One [...] Read more.
Glioblastoma is the most common and malignant primary brain tumor, defined by its highly aggressive nature. Despite the advances in diagnostic and surgical techniques, and the development of novel therapies in the last decade, the prognosis for glioblastoma is still extremely poor. One major factor for the failure of existing therapeutic approaches is the highly invasive nature of glioblastomas. The extreme infiltrating capacity of tumor cells into the brain parenchyma makes complete surgical removal difficult; glioblastomas almost inevitably recur in a more therapy-resistant state, sometimes at distant sites in the brain. Therefore, there are major efforts to understand the molecular mechanisms underpinning glioblastoma invasion; however, there is no approved therapy directed against the invasive phenotype as of now. Here, we review the major molecular mechanisms of glioblastoma cell invasion, including the routes followed by glioblastoma cells, the interaction of tumor cells within the brain environment and the extracellular matrix components, and the roles of tumor cell adhesion and extracellular matrix remodeling. We also include a perspective of high-throughput approaches utilized to discover novel players for invasion and clinical targeting of invasive glioblastoma cells. Full article
(This article belongs to the Special Issue Research in Aggressive Brain Tumors: Biology and Precision Therapy)
Show Figures

Figure 1

Back to TopTop